[{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immodulon Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon Therapeutics \/ Champalimaud Foundation"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Precision-Panc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immodulon Therapeutics \/ Precision-Panc","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon Therapeutics \/ Precision-Panc"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VTP-800","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SCIB1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Oleclumab","moa":"5'-nucleotidase","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Feladilimab","moa":"Inducible T-cell costimulator","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5'-nucleotidase","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD0486","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I | Tumor-associated calcium signal transducer 2","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Iteos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ iTeos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ iTeos Therapeutics"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mina Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EP0057","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AZD4573","moa":"Cyclin-dependent kinase 9 (CDK9)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP0057","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"Vivacitas Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Silatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"IAG, Image Analysis Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IAG, Image Analysis Group \/ Vivacitas Oncology","highestDevelopmentStatusID":"8","companyTruncated":"IAG, Image Analysis Group \/ Vivacitas Oncology"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgemcitabine Palabenamide","moa":"RRM1","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Volrustomig","moa":"CTLA4","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Volrustomig","moa":"CTLA4","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZD0486","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milciclib","moa":"Cyclin-dependent kinase 1 | Nerve growth factor receptor Trk-A | Cyclin-dependent kinase 4 | Cyclin-dependent kinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ART0380","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milciclib","moa":"||Cyclin-dependent kinase 1 | Nerve growth factor receptor Trk-A | Cyclin-dependent kinase 4 | Cyclin-dependent kinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AZD4635","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adavosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"AstraZeneca | Sharp | Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imperial College London \/ AstraZeneca | Sharp | Natera","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ AstraZeneca | Sharp | Natera"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Eli Lilly"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART4215","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||Cyclooxygenase","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS England \/ University of Manchester"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Reaction Biology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adavosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Reaction Biology","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Reaction Biology"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Partnership","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Imperial College London"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ART0380","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"CellCentric","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Inobrodib","moa":"||CREBBP\/EP300","graph1":"Oncology","graph2":"Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"CellCentric \/ Pfizer Inc"},{"orgOrder":0,"company":"CellCentric","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"Inobrodib","moa":"||CREBBP\/EP300","graph1":"Oncology","graph2":"Phase II","graph3":"CellCentric","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"CellCentric \/ RA Capital Management"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Mayo Clinic | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PolyPEPI1018 CRC Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Mayo Clinic | F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Mayo Clinic | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Antev","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teverelix Trifluoroacetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Antev","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antev \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antev \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Immunocore | Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"Melanocyte protein PMEL","graph1":"Oncology","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Oxford \/ Immunocore | Natera","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Immunocore | Natera"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCB008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Imperial College London \/ Pfizer Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Momelotinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"VDAC\/HK2 interaction","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"VDAC\/HK2 interaction","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Luminous Ventures"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AZD0171","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Volrustomig","moa":"CTLA4","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TCB008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"Serine-protein kinase ATR","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"CellCentric","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inobrodib","moa":"CREBBP|EP300","graph1":"Oncology","graph2":"Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellCentric \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CellCentric \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD0901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"PolyPEPI1018","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Shanghai Junshi Biosciences"}]
Find Oncology Drugs in Phase II Clinical Development in UNITED KINGDOM
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
